NCT03284177 - A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

December 4, 2018

Study Completion Date

December 4, 2018

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG

Calcium (13C)Carbonate

C13-CAC breath test containing Calcium (13C) Carbonate was performed twice under fasting conditions.

DRUG

Gastric acid inhibitors

Gastric acid inhibitor was orally administrated once daily for 4weeks after first C13-CAC breath test.

OTHER

Gastric pH monitoring

Gastric pH monitoring was performed once under fasting condition.

Trial Locations (13)

Akita University Hospital, Akita

National Hospital Organization Hakodate Hospital, Hakodate

Shimane University Hospital, Izumo

Kawasaki Medical School General Medical Center, Kurashiki

Kawasaki Medical School Hospital, Kurashiki

National Hospital Organization Matsumoto Medical Center, Matsumoto

Hyogo College Of Medicine College Hospital, Nishinomiya

Osaka Saiseikai Nakatsu Hospital, Osaka

Center Hospital of the National Center for Global Health and Medicine, National Research and Development Agency, Tokyo

Hiratsuka stomach and intestines Hospital, Tokyo

Nippon Medical School Hospital, Tokyo

National Hospital Organization Yokohama Medical Center, Yokohama

Yokohama City University Hospital, Yokohama